ClinicalTrials.gg
Not yet recruitingNCT07939997Updated Nov 16, 2026

ctDNA Observational Biomarker Validation Study for Evaluation of Esophageal Squamous Cell Carcinoma

An observational study in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by University of Colorado, Denver. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Colorado, Denver · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States — 42 open to participants now, 50 under way, 3 of them phase 3. Esophageal Squamous Cell Carcinoma · United States.

Started
2027
the only one that year
Observational
6 of 138
5 open now
Primary completion
2030-08
later than 45 of 49 live
Registered
138th of 138
by date

Among the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States, this one is the only one that started in 2027, is one of 6 observational ones, reaches primary completion later than 45 of the 49 other live ones, and was the 138th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 267 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

42 of the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to determine whether circulating tumor DNA (ctDNA) clearance at the completion of chemoradiotherapy (chemotherapy and radiation therapy) can predict durable complete response in adults with localized esophageal squamous cell carcinoma (ESCC). ctDNA clearance refers to the disappearance of detectable tumor DNA from the blood after treatment.

Current methods used to assess treatment response, including imaging scans (PET/CT) and endoscopy, have limitations in reliably identifying patients who achieve a durable complete response after chemoradiotherapy. Researchers will evaluate whether ctDNA clearance improves the prediction of durable complete response beyond standard response assessments. The findings may help identify patients suitable for non-operative management with active surveillance.

The main questions this study aims to answer are:

  • Can ctDNA clearance after chemoradiotherapy predict 2-year complete response-disease-free survival?
  • Can ctDNA clearance improve the prediction of durable complete response compared with standard response assessment methods, including PET/CT and endoscopy?
  • Can ctDNA clearance at different timepoints during and after chemoradiotherapy help identify patients at risk of disease recurrence?

The study will enroll approximately 120 adults with localized esophageal squamous cell carcinoma undergoing curative-intent chemoradiotherapy as part of standard clinical care.

Study participants will:

  • Provide blood samples at baseline, during Week 3 of chemoradiotherapy, and at completion of chemoradiotherapy for ctDNA analysis.
  • Participate in one of two observational cohorts. Participants in the Longitudinal ctDNA Cohort will provide additional blood samples at 6 weeks and 3 months after chemoradiotherapy and every 3 months through 24 months. Participants in the Limited-Sampling Research Cohort will provide only three protocol-required blood samples.
  • Continue standard-of-care cancer treatment and follow-up according to treating physician discretion.
  • Allow researchers to review medical records to assess treatment response, cancer recurrence, salvage therapy, and survival status through 24 months after completion of chemoradiotherapy.

Researchers will compare ctDNA results with standard clinical response assessments, including PET/CT and endoscopy, and clinical outcomes. Researchers will also assess whether ctDNA results influence physician treatment recommendations and clinical decision-making in the Longitudinal ctDNA Cohort.

This observational study does not involve investigational therapeutic interventions or require changes to standard clinical management. The findings may help improve risk stratification and identify patients suitable for organ-preservation strategies or closer surveillance following chemoradiotherapy.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma (ESCC)

Keywords

  • Esophageal Cancer
  • Locally Advanced Esophageal Squamous Cell Carcinoma
  • Cervical Esophageal Squamous Cell Carcinoma
  • Thoracic Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18 years or older with histologically confirmed, localized cervical or thoracic esophageal squamous cell carcinoma (ESCC), clinical stage cT1-4 or cTX, N0-3, M0, who are planned to receive curative-intent definitive chemoradiotherapy with active surveillance or neoadjuvant chemoradiotherapy followed by planned esophagectomy.

Eligible participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, adequate pretreatment tumor tissue for tumor-informed circulating tumor DNA (ctDNA) assay generation, and the ability to undergo protocol-specified blood collection.

Participants will be enrolled into one of two observational cohorts: the Longitudinal ctDNA Cohort or the Limited-Sampling Research Cohort. Cohort assignment will be based on participant election, treatment location, and operational feasibility. Participants may receive chemoradiotherapy at participating study sites or, for eligible participants in the Limited-Sampling Research Cohort,

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision to sign and date the consent form.
  • Stated willingness to comply with all study procedures and be available for the duration of the study.
  • Age ≥18 years.
  • confirmed cervical or thoracic esophageal squamous cell carcinoma (ESCC). For cervical tumors (defined per NCCN as \<5 cm from cricopharyngeus), the primary site must be the cervical esophagus rather than a primary hypopharyngeal as determined by the treating multidisciplinary team.
  • Clinical stage cT1-4 or cTX, N0-3, M0 disease according to AJCC 8th Edition staging, based on available standard-of-care staging studies and treating investigator assessment. EUS is not required when nodal disease or other standard staging information is sufficient to support treatment with chemoradiotherapy
  • Planned treatment with curative-intent chemoradiotherapy, including either:
  • definitive chemoradiotherapy with surveillance intent, or chemoradiotherapy with planned esophagectomy. Induction chemotherapy prior to chemoradiation is allowed, as well as the use of immunotherapy during the treatment course per physician discretion as part of curative-intent therapy.
  • For thoracic or cervical ESCC, the planned radiation dose and fractionation must be consistent with a definitive chemoradiotherapy regimen according to institutional standards, regardless of whether treatment is delivered with neoadjuvant or definitive intent.
  • Availability of pretreatment tumor tissue adequate for tumor-informed ctDNA assay generation.
  • Ability to undergo protocol-specified peripheral blood collection for ctDNA analysis according to the assigned cohort, including mobile phlebotomy when applicable.
  • performance status 0-2.
  • Adequate baseline clinical evaluation completed per institutional standard, including staging PET/CT and endoscopic assessment.

Exclusion criteria

Exclusion Criteria:

  • Evidence of (M1) disease.
  • Histology other than squamous cell carcinoma (including adenocarcinoma, small cell carcinoma, or mixed histology with predominant non-squamous features).
  • Prior thoracic radiotherapy overlapping planned treatment fields.
  • Inability to obtain adequate tumor tissue for ctDNA assay generation.
  • Active second requiring systemic therapy that could confound ctDNA interpretation, except adequately treated non-melanoma skin cancer or localized malignancies under surveillance.
  • Patients unable or unwilling to comply with serial blood collection or clinical follow-up requirements of either study cohort.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • CLEAR-ESO Longitudinal ctDNA Cohort

    The Longitudinal ctDNA Cohort additionally obtains ctDNA at 6 weeks post-CRT, 3 months post-CRT, and every 3 months through 24 months, and physician decision-impact surveys assess whether ctDNA findings influence clinical management.

    Diagnostic Test: Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay)

  • CLEAR-ESO Limited-Sampling Research Cohort

    Participants in the Limited-Sampling Research Cohort undergo tumor-informed ctDNA assessment at baseline, Week 3 of CRT, and completion of CRT. Results are returned through routine clinical workflows. No physician decision-impact surveys are administered, and no protocol-directed ctDNA collections occur after completion of CRT. Clinical outcome data are collected through approximately 24 months following CRT.

    Diagnostic Test: Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay)

Interventions

  • Diagnostic testTumor-Informed ctDNA Assessment (Signatera™ Genome Assay)

    Peripheral blood samples are collected for tumor-informed circulating tumor DNA (ctDNA) assessment using the Signatera™ Genome Assay. ctDNA testing is performed at protocol-defined time points to evaluate ctDNA clearance and kinetics in participants with localized esophageal squamous cell carcinoma undergoing standard-of-care chemoradiotherapy. Results are returned through routine clinical workflows; no protocol-mandated treatment modifications are required based on ctDNA results.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving 2-Year Complete Response-Disease-Free Survival (CR-DFS)

    The percentage of participants achieving 2-year complete response-disease-free survival (CR-DFS) across both neoadjuvant and definitive chemoradiotherapy (CRT) pathways. CR-DFS is defined as pathologic complete response (ypT0N0) among participants undergoing esophagectomy or sustained clinical complete response among participants managed with definitive CRT and active surveillance, without locoregional recurrence, distant recurrence, death, or requirement for salvage esophagectomy within 24 months of completing CRT. The primary analysis will compare 2-year CR-DFS rates between participants with and without circulating tumor DNA (ctDNA) clearance at completion of CRT, stratified by treatment pathway. ctDNA clearance is defined as conversion from detectable ctDNA at baseline to an undetectable result at completion of CRT. A common odds ratio with a 95% confidence interval will be reported.

    Time frame: From completion of chemoradiotherapy through 24 months post-chemoradiotherapy.

Secondary outcomes

  1. Sensitivity of ctDNA Clearance for Predicting 2-Year CR-DFS

    Sensitivity of ctDNA clearance at completion of CRT for identifying participants who achieve 2-year CR-DFS, calculated using ctDNA clearance status and the observed 2-year clinical outcome. Diagnostic performance will be summarized with 95% confidence intervals.

    Time frame: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.

  2. Specificity of ctDNA Clearance for Predicting 2-Year CR-DFS

    Specificity of ctDNA clearance at completion of CRT for identifying participants who do not achieve 2-year CR-DFS, calculated using ctDNA clearance status and the observed 2-year clinical outcome. Diagnostic performance will be summarized with 95% confidence intervals.

    Time frame: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.

  3. Positive Predictive Value of ctDNA Clearance for Predicting 2-Year CR-DFS

    Positive predictive value of ctDNA clearance at completion of CRT for identifying participants who achieve 2-year CR-DFS. Diagnostic performance will be summarized with 95% confidence intervals

    Time frame: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.

  4. Negative Predictive Value of ctDNA Clearance for Predicting 2-Year CR-DFS

    Negative predictive value of ctDNA clearance at completion of CRT for identifying participants who do not achieve 2-year CR-DFS. Diagnostic performance will be summarized with 95% confidence intervals.

    Time frame: Baseline and completion-of-CRT ctDNA assessment; clinical outcome assessment through 24 months post-CRT.

  5. Area Under the Receiver Operating Characteristic Curve (AUC) for ctDNA Clearance, PET/CT, Endoscopy, and Combined Models in Predicting 2-Year CR-DFS

    Area under the receiver operating characteristic curve (AUC) for ctDNA clearance, PET/CT response, endoscopic response, and combined models for predicting 2-year CR-DFS. Comparative and additive predictive performance will be evaluated to assess the incremental predictive value of ctDNA clearance over standard post-treatment response assessment.

    Time frame: Post-treatment response assessment following completion of CRT; clinical outcome assessment through 24 months post-CRT.

  6. Association Between ctDNA Clearance at Week 3 of CRT and 2-Year CR-DFS

    Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol.

    Time frame: Baseline and Week 3 of CRT; outcomes through 24 months post-CRT

  7. Association Between ctDNA Clearance at Completion of CRT and 2-Year CR-DFS

    Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol.

    Time frame: Baseline and Week 5 of chemoradiotherapy for thoracic tumors or Week 7 of chemoradiotherapy for cervical tumors; clinical outcomes assessed up to 24 months after completion of chemoradiotherapy

  8. Association Between ctDNA Clearance at 6 Weeks Post-CRT and 2-Year CR-DFS

    Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol.

    Time frame: Baseline through 6 weeks post-CRT; outcomes through 24 months post-CRT

  9. Association Between ctDNA Clearance at 3 Months Post-CRT and 2-Year CR-DFS

    Association between ctDNA clearance status at the specified landmark timepoint and subsequent 2-year complete response-disease-free survival (CR-DFS). ctDNA clearance is evaluated using the tumor-informed Signatera Genome Assay. Associations with 2-year CR-DFS will be evaluated using the statistical methods specified in the protocol.

    Time frame: Baseline through 3 months post-CRT; outcomes through 24 months post-CRT

  10. Percentage of Participants With Physician-Reported Changes in Clinical Management Attributable to ctDNA Results

    Frequency and type of physician-reported changes in treatment recommendations or surveillance strategy attributable to ctDNA results, including additional diagnostic testing and/or changes in clinical management. Changes will be assessed using the CLEAR-ESO Physician Decision-Impact Survey in the Longitudinal ctDNA Cohort only.

    Time frame: At 3 months and 24 months post-CRT and whenever ctDNA results influence clinical management, through 24 months post-CRT.

  11. Percentage of Participants With ctDNA Clearance According to Baseline Tumor Characteristics

    The percentage of participants achieving circulating tumor DNA (ctDNA) clearance at completion of chemoradiotherapy (CRT) will be evaluated according to baseline tumor characteristics, including clinical tumor stage, nodal stage, tumor length (cranial-caudal extent), baseline ctDNA burden, and cervical versus thoracic tumor location. ctDNA clearance is defined as conversion from detectable ctDNA at baseline to an undetectable result at completion of CRT.

    Time frame: Baseline through completion of chemoradiotherapy (approximately Week 5 for thoracic tumors and up to Week 7 for cervical tumors).

  12. Percentage of participants with Locoregional or Distant Recurrence according to ctDNA Status

    The percentage of participants experiencing locoregional or distant recurrence will be evaluated according to circulating tumor DNA (ctDNA) status during surveillance. Recurrence patterns will be characterized using available clinical and radiographic assessments.

    Time frame: From completion of chemoradiotherapy through 24 months post-chemoradiotherapy.

  13. Time From ctDNA Positivity to Radiographic or Clinical Recurrence

    Interval from ctDNA positivity during surveillance to radiographic or clinical recurrence among participants with documented recurrence. This analysis will characterize the timing of recurrence relative to ctDNA status in the Longitudinal ctDNA Cohort.

    Time frame: From completion of CRT through 24 months post-CRT.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2027; primary completion for Aug 2030, 38 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 16, 2026
StartEst.
Jun 2027
Primary completionEst.
Aug 24, 2030
CompletionEst.
Aug 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07939997
Collaborators
Natera, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jun 2027 (estimated)
Primary completion
Aug 24, 2030 (estimated)
Completion
Aug 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Chitra Pai Kulyadi
Contact
chitra.paikulyadi@cuanschutz.edu
857-919-8557
David Binder, MD, PhD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion